TD Waterhouse Canada’s Cytokinetics CYTK Stock Holding History

TD Waterhouse Canada’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-500	Closed	-$31.8K	–	2335
2025 Q4	$31.8K	Buy	+500	New	+$31.1K	﹤0.01%	1295

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TD Waterhouse Canada's CYTK Position: Q1 2026 in Review

TD Waterhouse Canada sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 500 shares — an estimated $31.8K sold.

TD Waterhouse Canada first reported a position in CYTK in Q4 2025 and held it in 1 quarter. The position peaked at $31.8K in Q4 2025. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

TD Waterhouse Canada reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
TD Waterhouse Canada sold 500 Cytokinetics shares in Q1 2026, an estimated $31.8K.
TD Waterhouse Canada first reported a position in Cytokinetics in Q4 2025 and held it in 1 quarter.
TD Waterhouse Canada's Cytokinetics position peaked at $31.8K in Q4 2025.
440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.